Titlebook: Endocrine Therapy of Breast Cancer IV; A. Goldhirsch Conference proceedings 1990 Springer-Verlag Berlin Heidelberg 1990 Hormonrezeptoren.O

信條

angina-pectoris

一致性

Molecular Genetics of Steroid Hormone Receptors,equent growth of breast cancer cells are hormonally regulated, and elucidation of the mechanisms of these processes requires an understanding of the structure and function of hormonal receptors. Moreover, receptor determination in tumour biopsies has now been used for many years as a means of predic

kindred

Prognostic Factors in Breast Cancer,selection of high- and low-risk patients. In the current discussion on the application of systemic adjuvant therapy in primary breast cancer, identification of high- and low-risk patients is a major issue [1]. Several classical (Table 1) and second generation prognostic factors (proliferation rate,

Airtight

Long-Term Tamoxifen Therapy: An Appropriate Chemosuppressive Treatment for Breast Cancer,acy as an adjuvant in node-positive disease [3,4] and increasing numbers of node-negative breast cancer patients are being treated with tamoxifen [5]. A remarkable feature of treatment with tamoxifen is the low incidence of side effects [1,3]. These clinical observations and the large body of eviden

不法行為

Tamoxifen as an Agonist for Metastatic Breast Cancer,e-effect profile, it has become the treatment of first choice for patients with locally advanced and metastatic breast cancer. Phase III clinical trials indicate that it is as effective as older treatments, for example, oe- strogens [2], but has fewer side effects. In premenopausal women, treatment

geometrician

Adjuvant Chemotherapy in Premenopausal Breast Cancer Patients is Effective by Means Other than Ovar, we analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women included in a randomised trial. There were 4 distinct subpopulations defined by nodal status and therapy: in a group with node-negative disease (552 patients), one course of cytotoxic

Modicum

管理員

https://doi.org/10.1007/978-3-642-75948-2Hormonrezeptoren; Ovarsuppression; breast cancer; cancer; carcinogenesis; cell; chemotherapy; genetics; horm

interlude